journal contribution
posted on 2023-03-31, 00:42 authored by Arabella Young, Shin Foong Ngiow, Jason Madore, Julia Reinhardt, Jennifer Landsberg, Arash Chitsazan, Jai Rautela, Tobias Bald, Deborah S. Barkauskas, Elizabeth Ahern, Nicholas D. Huntington, Dirk Schadendorf, Georgina V. Long, Glen M. Boyle, Michael Hölzel, Richard A. Scolyer, Mark J. Smyth This file contains Supplementary experimental Procedures, Supplementary Figure Legends, and Table S1. Table S1. Changes to patient CD73 expression following BRAF targeted therapy.
Funding
National Health and Medical Research Council
NHMRC
Cancer Research Institute
EMBO
European Commission
History
ARTICLE ABSTRACT
Increasing evidence exists for the role of immunosuppressive adenosine in promoting tumor growth and spread in a number of cancer types, resulting in poor clinical outcomes. In this study, we assessed whether the CD73-adenosinergic pathway is active in melanoma patients and whether adenosine restricts the efficacy of clinically approved targeted therapies for commonly mutated BRAFV600E melanoma. In AJCC stage III melanoma patients, CD73 expression (the enzyme that generates adenosine) correlated significantly with patients presenting nodal metastatic melanoma, suggesting that targeting this pathway may be effective in advanced stage disease. In addition, dabrafenib and trametinib treatment of CD73+ BRAFV600E-mutant melanomas caused profound CD73 downregulation in tumor cells. Inhibition of BRAF and MEK in combination with the A2A adenosine receptor provided significant protection against tumor initiation and metastasis formation in mice. Our results suggest that targeting adenosine may enhance therapeutic responses for melanoma patients receiving targeted or immune-based therapies. Cancer Res; 77(17); 4684–96. ©2017 AACR.
